{"id":"W2010818649","doi":"10.3747/co.v16i0.404","title":"Targeted Therapies for Renal Cell Carcinoma: More Gains from Using Them Again","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Imatinib; Sorafenib; Nilotinib; Chronic myelogenous leukemia; Dasatinib; Concomitant; Tyrosine-kinase inhibitor; Renal cell carcinoma; Tyrosine kinase; Oncology; Bevacizumab; Targeted therapy; Temsirolimus; Internal medicine; Pharmacology; Leukemia; Cancer; Chemotherapy; Myeloid leukemia; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01431752,0.0009522666,0.002296405,0.001565516,0.0006631251,0.00505804,0.001532997,0.003845641,0.01519748],"category_scores_gemma":[0.01137482,0.0003045825,0.001927671,0.001140028,0.003677487,0.014254,0.001903647,0.01053614,0.004419675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002317707,"about_ca_system_score_gemma":0.002519737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001731754,"about_ca_topic_score_gemma":0.004332962,"domain_scores_codex":[0.995966,0.001684691,0.000384909,0.0004374408,0.001194684,0.0003323183],"domain_scores_gemma":[0.9881868,0.006341973,0.0007875351,0.001260458,0.002308856,0.001114392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009589465,0.0005025618,0.001581053,0.004060559,0.0002967215,0.0003909959,0.000342108,0.0007410444,0.003601211,0.05388874,0.1137308,0.8199052],"study_design_scores_gemma":[0.0003141316,0.0007828709,0.001767409,0.002922883,0.0001978736,0.0007002768,0.0003858653,0.0003886673,0.0008703614,0.03655815,0.9550391,0.00007238648],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.002653788,0.8045571,0.005849147,0.1682956,0.008501333,0.00005349522,0.0001601969,0.0001735953,0.009755662],"genre_scores_gemma":[0.03543174,0.8009057,0.01051506,0.1126058,0.03014927,0.0001323968,0.0003154529,0.0002107382,0.009733797],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01519748,"threshold_uncertainty_score":0.07571918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1574497299406017,"score_gpt":0.3932410952658096,"score_spread":0.2357913653252079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}